StockData
TriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc. (TLSI) stock

TLSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TLSIW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$2.45+0.16 (+6.75%)

Close on Nov 18, 2026Market cap $150.86MP/E –Yield –

Earnings

TriSalus Life Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$12.90M
+11.2% on a year earlier
EPS, Q3 FY2026
-$0.15
-$0.96 a year earlier
Latest guidance
Lowered
Nov 10, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of TriSalus Life Sciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open$12.90M+11.2%-$0.15Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$11.40M+1.8%-$0.16Release
Q1 FY2026ended Mar 31, 2026May 12, 2026after the close$8.90M-3.3%$0.03Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026after the close$13.20M+59.0%-$0.21Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025after the close$11.60M+58.9%-$0.96Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close$11.20M+51.4%-$0.27Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open$9.20M+41.5%-$0.39Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025before the open$8.30M–-$0.40Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open$7.30M+40.4%-$0.12Release
Q2 FY2024ended Jun 30, 2024Aug 15, 2024before the open$7.40M–-$0.21Release
Q1 FY2024ended Mar 31, 2024May 15, 2024before the open$6.50M–-$0.60Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

TriSalus Life Sciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
full-year 2026 revenue guidanceFY2026$54.00M – $57.00M$54.00M – $57.00MReaffirmedAug 6, 2026
growthFY2026+19% – +26%–NewAug 6, 2026
revenue guidanceFY2026$46.00M – $48.00M$60.00M – $62.00MLoweredNov 10, 2026

Guidance vs results

The last range TriSalus Life Sciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue growth+50%+53.22%Σ4QAbove range

Guidance history

Every forecast TriSalus Life Sciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026revenue guidanceFY2026$46.00M – $48.00MLowered
Aug 6, 2026growthFY2026+19% – +26%New
Aug 6, 2026full-year 2026 revenue guidanceFY2026$54.00M – $57.00MReaffirmed
May 12, 2026revenue guidanceFY2026$54.00M – $57.00MLowered
Mar 5, 2026revenuesFY2026$60.00M – $62.00MNew
Jan 12, 2026full-year revenuesFY2026$60.00M – $62.00MNew
Nov 13, 2025full-year revenue growthFY2025+50%New
Aug 12, 2025revenue growthFY2025+50%Reaffirmed
May 15, 2025revenueFY2025+50%Reaffirmed
Mar 27, 2025Gross marginsFY202587%New
Mar 27, 2025Operating expensesFY2025+20%New
Mar 27, 2025SalesFY2025+50%Reaffirmed
Jan 23, 2025revenueFY2025+50%Reaffirmed
Nov 14, 2024reduction in operating expensesFY202520%New
Nov 14, 2024sales growthFY2025+50%New
May 15, 2024sales growthFY2024+50%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases TriSalus Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. Results
  4. Results
  5. Update
  6. Results
  7. News
  8. News
  9. Update
  10. Results
  11. Results
  12. Results
  13. News
  14. News
  15. News

See a number that looks wrong?